Skip to content 
Search

Latest Stories

New 'Nimbus' Covid variant could trigger summer infection wave, experts warn

UKHSA data up to 1 June reveals that 6.1 per cent of those tested for Covid were positive

Experts Warn Nimbus (NB.1.8.1) May Trigger COVID Summer Wave

‘Nimbus’, is raising concerns among health experts

iStock

A new highly transmissible Covid variant, known as ‘Nimbus’, is raising concerns among health experts as cases rise sharply in parts of Asia and begin to appear in the UK. Official data shows that the strain, which has been labelled N.B.1.8.1, could drive a summer wave of infections due to its increased contagiousness and potential to evade immunity from earlier vaccinations or infections.

Cases detected in the UK

According to the UK Health Security Agency (UKHSA), 13 confirmed cases of the variant have already been recorded in England, and 25 British samples have been submitted to international databases since the end of March. However, experts say these figures likely underestimate the true spread, given the current limited Covid testing regime compared to the height of the pandemic.


UKHSA data up to 1 June reveals that 6.1 per cent of those tested for Covid were positive—the highest weekly figure for 2025. This marks a 7 per cent increase from the previous week and a 97 per cent rise compared to early March.

Rapid international spread

Nimbus, which is a descendant of the Omicron family of variants, has been linked to a spike in cases in China, Singapore, and Hong Kong. Globally, it now accounts for around 10.7 per cent of Covid infections, up from just 2.5 per cent a month earlier, according to the World Health Organisation (WHO).

The WHO has designated the variant as a ‘variant under monitoring’, which means it is being tracked for its potential impact but is not currently classified as a variant of concern.

Scientists warn of summer spike

British scientists are now warning that the new strain could fuel a rise in cases over the summer months, particularly as people become more socially active during the warmer weather.

Professor Lawrence Young, a virologist at Warwick University, said: “We are very likely to see a spike of infections over the next couple of months, possibly by later this month or in July. But it’s difficult to predict the level of this infection wave.”

He explained that population immunity from previous vaccinations or infections is likely waning, and unlike flu, Covid continues to spread in hot and humid weather. Laboratory studies also suggest that Nimbus is more efficient at infecting human cells and may have enhanced abilities to evade the immune system.

No evidence of increased severity

Despite its contagiousness, there is currently no indication that Nimbus causes more severe illness or higher mortality rates than earlier strains. However, experts caution that vulnerable groups—such as the elderly, people in care homes, and those with weakened immune systems—remain at risk of serious illness.

Data from the Office for National Statistics indicates that Covid contributed to just over 300 deaths in England during May 2025.

Symptoms and vaccine protection

The symptoms of the Nimbus variant appear to be consistent with those of previous Covid strains. These include fatigue, fever, sore throat and muscle aches.

There is currently no suggestion that the variant causes different or more severe symptoms. Moreover, scientists believe that existing Covid vaccines, reformulated to tackle Omicron and its descendants, should still offer protection against Nimbus.

UKHSA data shows that people who received a Covid booster last spring were 45 per cent less likely to require hospital treatment compared to those who remained unvaccinated.

Who is eligible for the vaccine?

In the UK, free Covid vaccinations are currently being offered to:

  • Adults over the age of 75
  • Residents and staff in care homes
  • Individuals with weakened immune systems

The UKHSA has urged all eligible people to take up the vaccine offer to help protect themselves and others from severe illness, particularly with the rising presence of the Nimbus strain.

Officials closely monitoring situation

Dr Gayatri Amirthalingam, deputy director at UKHSA, confirmed that the agency is closely tracking the spread of the N.B.1.8.1 variant both domestically and internationally.

“UKHSA is monitoring all available data relating to SARS-CoV-2 variants in the UK and abroad, and we continue to publish our findings in our regular Flu and Covid-19 surveillance reports,” she said.

“NB.1.8.1 has been detected in small numbers in the UK to date, but international data suggests that it is growing as a proportion of all Covid-19 cases.”

As the summer approaches, experts are reminding the public that even though the pandemic is no longer dominating daily life, Covid continues to evolve. The emergence of Nimbus underscores the need for vigilance, particularly among those at higher risk.

More For You

HPV vaccine 16 to 25

Many of those targeted missed their vaccine during school years

iStock

NHS steps up HPV vaccine rollout for young people aged 16–25

Highlights

  • NHS encourages unvaccinated people aged 16–25 to get the HPV vaccine
  • Over 418,000 school leavers in past three years missed vaccination
  • HPV vaccine protects against cervical and other related cancers
  • NHS aiming for 90% uptake among girls by 2040
  • Letters, emails, texts and NHS App alerts being used for reminders

NHS campaign targets unvaccinated young adults

The NHS is urging hundreds of thousands of young people aged 16 to 25 to come forward for the HPV vaccine, which protects against cervical and other types of cancer.

Many of those targeted missed their vaccine during school years. According to NHS England, over 418,000 children left school without receiving the HPV jab in the past three years.

Keep ReadingShow less
Bryan Johnson

He now believes that commercial interests may be at odds with his philosophical mission

Getty Images

Bryan Johnson may shut down anti-ageing startup to focus on religion

Highlights

  • Bryan Johnson, 47, is contemplating shutting down or selling his anti-ageing startup, Blueprint.
  • The biotech entrepreneur recently launched a religion called "Don’t Die."
  • He says commercial activity is undermining his philosophical credibility.
  • Blueprint has faced financial pressures but Johnson denies any crisis.

Biotech entrepreneur and longevity enthusiast Bryan Johnson has revealed he is considering shutting down or selling his anti-ageing company, Blueprint. Speaking to Wired, the 47-year-old said his priorities have shifted towards developing his newly founded religion, "Don’t Die", which he believes better aligns with his philosophical ambitions.

“I am so close to either shutting it down or selling it,” Johnson said in the interview published Monday. “I don’t need the money, and it’s a pain-in-the-ass company.”

Keep ReadingShow less
slimming jab Morrisons

The move has sparked criticism on social media

iStock

Morrisons launches £129-a-month weight loss injection service

Highlights

  • Morrisons Clinic introduces subscription service for tirzepatide injections
  • The treatment may aid weight loss of up to 20% over one year
  • Monthly subscription will increase from £129 to £159 after introductory period
  • Service includes medical assessment and regular check-ins
  • Criticism emerges over the supermarket’s continued sale of unhealthy food


Morrisons has launched an online subscription service offering weight loss injections, prompting mixed reactions from the public. The supermarket’s online health platform, Morrisons Clinic, now offers tirzepatide — also known by the brand name Mounjaro — for weight management.

Tirzepatide is primarily prescribed to treat type 2 diabetes, but has also been approved for weight loss. According to Morrisons Clinic, users may lose up to 20 per cent of their body weight over the course of a year.

Keep ReadingShow less
RSV vaccine premature babies

NHS England says premature babies are three times more likely to be hospitalised due to RSV

iStock

NHS to immunise premature babies against deadly winter virus RSV

Highlights

  • NHS to offer nirsevimab injection to 9,000 premature and high-risk babies from late September
  • Aims to protect against respiratory syncytial virus (RSV), which can cause severe illness in infants
  • Premature babies are 10 times more likely to need intensive care for RSV
  • Nirsevimab offers immediate protection and lasts for six months
  • Neo-natal units across the UK will deliver the jab

Thousands of premature and high-risk babies in the UK will soon be offered a new immunisation to protect against RSV (respiratory syncytial virus), a common winter virus that can cause serious lung infections and hospitalisation. The NHS will begin delivering the nirsevimab injection from late September, aiming to shield vulnerable infants before the colder months set in.

Premature infants at higher risk from RSV

RSV typically causes coughs and colds, but in some children — particularly those born prematurely or with underlying health conditions — it can lead to bronchiolitis, pneumonia, and breathing difficulties. NHS England says premature babies are three times more likely to be hospitalised due to RSV and ten times more likely to require intensive care compared to full-term infants.

Keep ReadingShow less
Donald Trump health 2025

The diagnosis has prompted a wave of public attention

Getty Images

What is chronic venous insufficiency, the condition Donald Trump is diagnosed with?

Highlights

  • President Donald Trump has been diagnosed with chronic venous insufficiency (CVI), a vascular condition affecting blood flow in the legs
  • CVI occurs when leg veins struggle to return blood to the heart, often leading to swelling and discomfort
  • The condition was confirmed following visible leg swelling and bruising
  • Though not life-threatening, CVI can worsen without treatment
  • Trump’s case has sparked public interest in the risks and management of the condition

Trump diagnosed with common but chronic vein condition

President Donald Trump has been diagnosed with chronic venous insufficiency, a condition that affects the proper circulation of blood in the legs. The announcement followed public speculation after Trump was seen with visible swelling in his lower legs and bruising on his hand during recent public appearances.

According to a statement from White House medical staff, tests ruled out more serious cardiovascular conditions. Trump, 79, remains under regular observation, with the condition described as benign and manageable.

Keep ReadingShow less